C
88.34
-1.99 (-2.20%)
| Previous Close | 90.32 |
| Open | 91.00 |
| Volume | 714,259 |
| Avg. Volume (3M) | 824,576 |
| Market Cap | 9,308,011,520 |
| Price / Earnings (TTM) | 78.87 |
| Price / Earnings (Forward) | 26.32 |
| Price / Sales | 14.12 |
| Price / Book | 14.17 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 19.55% |
| Operating Margin (TTM) | 2.17% |
| Diluted EPS (TTM) | 1.15 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | -26.00% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 3.07 |
| Operating Cash Flow (TTM) | 179.44 M |
| Levered Free Cash Flow (TTM) | 160.08 M |
| Return on Assets (TTM) | 9.18% |
| Return on Equity (TTM) | 21.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bullish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.49% |
| % Held by Institutions | 80.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 145.00 (HC Wainwright & Co., 64.15%) | Buy |
| Median | 140.00 (58.49%) | |
| Low | 121.00 (Piper Sandler, 36.98%) | Buy |
| Average | 135.33 (53.20%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 75.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Oct 2025 | 145.00 (64.15%) | Buy | 73.96 |
| Canaccord Genuity | 25 Sep 2025 | 140.00 (58.49%) | Buy | 82.73 |
| 10 Sep 2025 | 140.00 (58.49%) | Buy | 71.62 | |
| Piper Sandler | 01 Aug 2025 | 121.00 (36.98%) | Buy | 69.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Sep 2025 | Announcement | Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 |
| 10 Sep 2025 | Announcement | FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer |
| 31 Jul 2025 | Announcement | Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update |
| 24 Jul 2025 | Announcement | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |